In the level of SPE of PRRX2, the survival rate of patients is significantly different (P < 0.05; log-rank test) (Fig. S16), demonstrating that stMGATF can identify hub upstream TFs closely associated with good prognosis in breast cancer patients through SDGs. Here, PRRX2 is linked to breast carcinoma.